Fluralaner

Fluralaner, (INN) sold under the brand name Bravecto among others, is a systemic insecticide and acaricide that is administered orally or topically. The US Food and Drug Administration (FDA) approved it for flea treatment in dogs in May 2014, and approved the combination fluralaner/moxidectin (Bravecto Plus) as a topical treatment for cats in November 2019. The EU approved fluralaner in March 2014. Australia approved it for the treatment and prevention of ticks and fleas on dogs in January 2015. For treating mites in chickens, a solution for use in drinking water is available under the brand name Exzolt and was approved for use in the EU in 2017.

Mode of action
Fluralaner inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABA$A$ receptors) and L-glutamate-gated chloride channels (GluCls). Potency of fluralaner is comparable to fipronil (a related GABA-antagonist insecticide and acaricide).

Research
Fluralaner is being investigated to determine its ability to reduce the incidence of mosquito-borne diseases, as well as bed bugs.